WO1998001100A3 - Method for treating homozygous familial hypercholesterolemia - Google Patents
Method for treating homozygous familial hypercholesterolemia Download PDFInfo
- Publication number
- WO1998001100A3 WO1998001100A3 PCT/US1997/011792 US9711792W WO9801100A3 WO 1998001100 A3 WO1998001100 A3 WO 1998001100A3 US 9711792 W US9711792 W US 9711792W WO 9801100 A3 WO9801100 A3 WO 9801100A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- familial hypercholesterolemia
- homozygous familial
- day
- treating
- treating homozygous
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU42289/97A AU4228997A (en) | 1996-07-09 | 1997-07-03 | Method for treating homozygous familial hypercholesterolemia |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2142096P | 1996-07-09 | 1996-07-09 | |
US60/021,420 | 1996-07-09 | ||
GBGB9617898.3A GB9617898D0 (en) | 1996-08-28 | 1996-08-28 | Method for treating homozygous familial hypercholesterolemia |
GB9617898.3 | 1996-08-28 | ||
US2935196P | 1996-10-31 | 1996-10-31 | |
US60/029,351 | 1996-10-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998001100A2 WO1998001100A2 (en) | 1998-01-15 |
WO1998001100A3 true WO1998001100A3 (en) | 1998-02-12 |
Family
ID=27268450
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/011792 WO1998001100A2 (en) | 1996-07-09 | 1997-07-03 | Method for treating homozygous familial hypercholesterolemia |
PCT/US1997/012426 WO1998001116A1 (en) | 1996-07-09 | 1997-07-03 | Therapy for combined hyperlipidemia |
PCT/US1997/010867 WO1998001119A2 (en) | 1996-07-09 | 1997-07-03 | Pharmaceutical compositions comprising simvastatin |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/012426 WO1998001116A1 (en) | 1996-07-09 | 1997-07-03 | Therapy for combined hyperlipidemia |
PCT/US1997/010867 WO1998001119A2 (en) | 1996-07-09 | 1997-07-03 | Pharmaceutical compositions comprising simvastatin |
Country Status (2)
Country | Link |
---|---|
AU (3) | AU3667297A (en) |
WO (3) | WO1998001100A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9493576B2 (en) | 2007-08-23 | 2016-11-15 | Amgen Inc. | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030212996A1 (en) * | 1996-02-08 | 2003-11-13 | Wolzien Thomas R. | System for interconnection of audio program data transmitted by radio to remote vehicle or individual with GPS location |
CN1197565C (en) * | 1998-09-30 | 2005-04-20 | 沃尼尔·朗伯公司 | Method for preventing or delaying catheter-based revascularization |
NZ527852A (en) | 2001-03-28 | 2005-03-24 | Schering Corp | Enantioselective synthesis of azetidinone intermediate compounds |
AU2002358468A1 (en) * | 2001-12-21 | 2003-07-15 | Rigshospitalet | Igamete recruitment and developmental competence in mammals by inhibiting the de novo sterol biosynthesis and/or promoting sterol efflux |
AR040588A1 (en) | 2002-07-26 | 2005-04-13 | Schering Corp | PHARMACEUTICAL FORMULATION INCLUDING AN INHIBITOR OF CHOLESTEROL ABSORPTION AND AN INHIBITOR OF A HMGCO TO REDUCTASE |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4997849A (en) * | 1989-06-23 | 1991-03-05 | Merck & Co., Inc. | Microbial transformation of simvastatin |
US5393893A (en) * | 1993-11-08 | 1995-02-28 | Apotex, Inc. | Process for producing simvastatin and analogs thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4806564A (en) * | 1987-05-26 | 1989-02-21 | Merck & Co., Inc. | Antihypercholesterolemic beta-lactones |
-
1997
- 1997-07-03 WO PCT/US1997/011792 patent/WO1998001100A2/en active Application Filing
- 1997-07-03 AU AU36672/97A patent/AU3667297A/en not_active Abandoned
- 1997-07-03 WO PCT/US1997/012426 patent/WO1998001116A1/en active Application Filing
- 1997-07-03 WO PCT/US1997/010867 patent/WO1998001119A2/en active Application Filing
- 1997-07-03 AU AU43261/97A patent/AU4326197A/en not_active Abandoned
- 1997-07-03 AU AU42289/97A patent/AU4228997A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4997849A (en) * | 1989-06-23 | 1991-03-05 | Merck & Co., Inc. | Microbial transformation of simvastatin |
US5393893A (en) * | 1993-11-08 | 1995-02-28 | Apotex, Inc. | Process for producing simvastatin and analogs thereof |
Non-Patent Citations (1)
Title |
---|
LANCET, November 1994, Vol. 19:344, "Randomised Trial of Cholesterol Lowering in 4444 Patients with Coronary Heart Disease: The Scandinavian Simvastatin Survival Study (4S)", pages 1383-9. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9493576B2 (en) | 2007-08-23 | 2016-11-15 | Amgen Inc. | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
Also Published As
Publication number | Publication date |
---|---|
WO1998001100A2 (en) | 1998-01-15 |
AU4326197A (en) | 1998-02-02 |
AU4228997A (en) | 1998-02-02 |
WO1998001116A1 (en) | 1998-01-15 |
WO1998001119A2 (en) | 1998-01-15 |
AU3667297A (en) | 1998-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2088254A1 (en) | Treatment for hypercholesterolemia | |
CA2289717A1 (en) | Novel therapy for constipation | |
HU9402771D0 (en) | Pharmaceutical compositions for wound healing and treatment of fibrotic disorders | |
AU5729098A (en) | Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes | |
EP1555025A3 (en) | Use of dehydroepiandrosterone analogs for the treatment of asthma | |
WO2000059487A3 (en) | Flupirtine in the treatment of fibromyalgia and related conditions | |
CA2370030A1 (en) | Sodium channel blocker compositions and the use thereof | |
CA2180535A1 (en) | A method for treatment of psoriasis, by omeprazole or related compounds | |
EP1576956A3 (en) | Chromium/biotin treatment of type II diabetes | |
WO2001030802A3 (en) | Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies | |
CA2150185A1 (en) | Pharmaceutical composition for the treatment of stoma-peripheral inflammation | |
WO1997003188A3 (en) | Use of mp52 or mp121 for treating and preventing diseases of the nervous system | |
PL323617A1 (en) | Pharmaceutical preparation for treating oestrogen-dependent carcinomas | |
AU6178198A (en) | Method of treating a tumor | |
WO2002039994A3 (en) | Methods for the treatment and prevention of urinary stone disease | |
WO1998001100A3 (en) | Method for treating homozygous familial hypercholesterolemia | |
WO2000012045A3 (en) | Method for treating neurodegenerative disorders | |
WO1996030042A3 (en) | Methods of treating inflammation and compositions therefor | |
WO1999048489A3 (en) | Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders | |
AU2196297A (en) | Methods of treating or preventing interstitial cystitis | |
AU5298699A (en) | Dnazymes and methods for treating hpv-related disorders | |
WO2000029012A3 (en) | Methods of alleviating cancer symptoms | |
AU3785497A (en) | Drug for the prevention or treatment of pollakiuria and urinary incontinence | |
AU3308099A (en) | Method for the treatment of pain, including chronic and female specific pain | |
AUPP379698A0 (en) | Using ngali nut oil to treat/relieve the pain of arthritis and other similar conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HU IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998505308 Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase |